Comparison of glycemic variability in Chinese T2DM patients treated with exenatide or insulin glargine: A randomized controlled trial
Diabetes Therapy May 25, 2018
Yin TT, et al. - In this prospective study, researchers compared patients on a glucagon-like peptide-1 (GLP-1) receptor agonist with patients on basal insulin in terms of glycemic variability using a continuous glucose monitoring system (CGMS). For 16 weeks, either exenatide treatment or insulin glargine treatment was received by type 2 diabetes mellitus (T2DM) patients treated with metformin. In addition to glycemic variability; hemoglobin A1c (HbA1c), β-cell function, weight, body mass index (BMI), and waist circumference were also assessed. In terms of glycemic variability, HbA1c alleviation, and β-cell function, exenatide and insulin glargine were found to be similarly efficacious in overweight and obese patients with T2DM inadequately controlled by metformin. However, exenatide was shown to have a greater impact on body weight and BMI.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries